Volume 1.45 | Nov 23

Hematopoiesis News 1.45, November 23, 2010.  
In this issue: Science News  |  Current Publications  |  Industry News  |  Policy News  |  Events Subscribe  |  Unsubscribe

TOP STORY

Transplantation of Mouse HSCs Genetically Modified to Express a CD4-Restricted TCR Results in Long-Term Immunity that Destroys Tumors and Initiates Spontaneous Autoimmunity  ShareThis
In this study, researchers sought to alter and enhance long-term host immunity by genetically modifying, then transplanting, mouse hematopoietic stem cells (HSCs). [J Clin Invest]

ProficiencyTesting_v01_645x110-Register


SPECIAL FEATURE

Interested in recruiting talented individuals? Post your career opportunities in Hematopoiesis News at no cost. Contact us at [email protected]

Follow us on Twitter! @Hema_News



SCIENCE NEWS

Gene Therapy for Metastatic Melanoma in Mice Produces Complete Remission, Indiana University Cancer Researchers Report
A potent anti-tumor gene introduced into mice with metastatic melanoma has resulted in permanent immune reconfiguration and produced a complete remission of their cancer, according to an article. [Press release from the Indiana University School of Medicine discussing online prepublication in the Journal of Clinical Investigation]

Request A Sample  
Column-Free Isolation of
Hematopoietic Stem and Progenitor Cells
with EasySep®
 
 
REQUEST A SAMPLE STEMCELL Technologies Inc
 


CURRENT PUBLICATIONS  (Ranked by Impact Factor of the Journal)

LABORATORY RESEARCH

Fine-Mapping at Three Loci Known to Affect Fetal Hemoglobin Levels Explains Additional Genetic Variation
Researchers used resequencing and genotyping in African Americans with sickle cell anemia to characterize associations with fetal hemoglobin levels at the BCL11A, HBS1L-MYB and beta-globin loci. [Nat Genet]

Zebrafish microRNA-126 Determines Hematopoietic Cell Fate through c-Myb
In this study, researchers show that miR-126 is a novel physiological regulator of the proto-oncogene c-myb during definitive hematopoiesis. [Leukemia]

DAMP-Mediated Autophagy Contributes to Drug Resistance
High mobility group box 1 (HMGB1) is a prototypical damage associated molecular pattern molecule (DAMP) and is associated with the hallmarks of cancer. Recently researchers found that HMGB1 release after chemotherapy treatment is a critical regulator of autophagy and a potential drug target for therapeutic interventions in leukemia. [Autophagy]

FIP200, an Essential Component of Mammalian Autophagy Is Indispensible for Fetal Hematopoiesis
Researchers show that mice lacking focal adhesion kinase family interacting protein of 200 kD (FIP200) in hematopoietic cells (CKO mice) experience perinatal lethality associated with severe erythroblastic anemia. [Autophagy]

HoxA10 Regulates Transcription of the Gene Encoding Transforming Growth Factor Beta 2 (TGFB2) in Myeloid Cells
The current study identifies the gene encoding transforming growth factor B2 (TGFB2) as a HoxA10-target-gene. [ J Biol Chem]

A New, Lineage Specific, Autoup-Regulation Mechanism for Human Glucocorticoid Receptor Gene Expression in 697 Pre-B-Acute Lymphoblastic Leukemia Cells
The data suggest a hormone activated, lineage-specific mechanism to control the autoup-regulation of human GC receptor (hGR ) gene expression in 697 pre-B-acute lymphoblastic leukemia cells via steroid-mediated changes in GR coregulator expression. [Mol Endocrinol]

CLINICAL RESEARCH

The Prognostic Impact and Stability of Isocitrate Dehydrogenase 2 Mutation in Adult Patients with Acute Myeloid Leukemia
Serial analyses of isocitrate dehydrogenase 2 (IDH2) mutations at both diagnosis and relapse in 121 patients confirmed high stability of IDH2 mutations. In conclusion, IDH2 mutation is a stable marker during disease evolution and confers favorable prognosis. [Leukemia]

Regulatory T Cells Predict the Time to Initial Treatment in Early Stage Chronic Lymphocytic Leukemia
Higher regulatory T cell levels had significant and independent prognostic power for predicting the time to initial treatment in patients with low to intermediate stage chronic lymphocytic leukemia. [Cancer]


INDUSTRY NEWS

Isis and Xenon Collaborate to Develop Antisense Drugs Against Hemojuvelin and Hepcidin
Isis Pharmaceuticals, Inc. and Xenon Pharmaceuticals Inc. announced a new collaboration to discover and develop antisense drugs as novel treatments for the common disease anemia of inflammation. [Isis Pharmaceuticals, Inc. Press Release]

AesRx Announces Collaboration with NIH to Develop Aes-103 for Sickle Cell Disease
AesRx, LLC, announced that it has entered into a collaboration with the National Institutes of Health (NIH) to take AesRx’s investigational sickle cell therapeutic, Aes-103, through pre-clinical development and initial clinical trials, including two trials in sickle cell patients. [AesRx, LLC, Press Release]

Bayer, J&J Anti-Clot Drug Shines in Stroke Trial
A once-daily pill being developed by Bayer AG and Johnson & Johnson was better at preventing stroke than standard treatment, with less risk of the most worrisome types of bleeding, researchers said. [Reuters]


EVENTS (Listed by Date)

52nd American Society of Hematology (ASH) Annual Meeting and Exposition
December 4-7, 2010
Orlando, United States

5th Annual Stem Cell Meeting on the Mesa
December 7, 2010
La Jolla, United States

The 3rd Guangzhou International Conference on Stem Cell Biology and Regenerative Medicine
December 17-19, 2010
Guangzhou, China

Highlights of American Society of Hematology (ASH) Vancouver
January 21-22, 2011
Vancouver, Canada

Highlights of American Society of Hematology (ASH) Washington, D.C.
January 28-29, 2011
Washington, D.C., United States

Highlights of American Society of Hematology (ASH) San Francisco
January 28-29, 2011
San Francisco, United States

Highlights of American Society of Hematology (ASH) New York
February 4-5, 2011
New York, United States

Highlights of American Society of Hematology (ASH) San Diego
February 4-5, 2011
San Diego, United States

BMT Tandem Meetings (ASBMT/CIBMTR)
February 17-21, 2011
Honolulu, Hawaii

Molecular Medicine Tri-Conference: Inaugural Circulating Tumor Cells for Cancer Detection, Diagnosis, Prognosis and Treatment
February 23-25, 2011
San Francisco, United States

American Association for Cancer Research (AACR) Stem Cells, Development, and Cancer
March 3-6, 2011
Vancouver, Canada

Keystone Symposia: Hematopoiesis
March 27-April 1, 2011
Big Sky, United States

United Kingdom National Stem Cell Network 2011 Annual Scientific Conference
March 30-April 1, 2011
York, United Kingdom

American Association for Cancer Research (AACR) 102nd Annual Meeting 2011
April 2-6, 2011
Orlando, United States

37th Annual Meeting of the European Group for Blood and Marrow Transplantation
April 3-6, 2011
Paris, France

International Society for Stem Cell Research (ISSCR) 9th Annual Meeting
June 15-18, 2011
Toronto, Canada

Visit our events page to stay up to date with the latest events in the cell, gene and immunotherapy community.

JOB OPPORTUNITIES

Lab Technologist – Human Embryonic and Induced Pluripotent Stem Cells (STEMCELL Technologies)

Lab Technologist – Tissue Culture (STEMCELL Technologies)


Product Manager – Pluripotent Stem Cells (STEMCELL Technologies)

Recruit Top Talent
Reach more than 11,000 potential candidates by posting your organization’s career opportunities with Cell Therapy News at no cost.

Visit here to post your career opportunities.


Have we missed an important article or publication in Hematopoiesis News? Click here to submit!




Comments or Suggestions? Email [email protected] with your feedback.


Learn more about Hematopoiesis News: Archives  |  Events  |  Subscribe  |  Contact Us